- Global Pharma News & Resources

CytoSorbents Expands Distribution of CytoSorb® to a Total of 53 Countries Worldwide

MONMOUTH JUNCTION, N.J., July 31, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has expanded the distribution of CytoSorb® to a total of 53 countries worldwide.

Recently added countries (and distributors), accounting for an additional 31 million people, include:

Lebanon – Pharma World LB

Bosnia, Herzegovina, and Croatia – Medis, d.o.o.

Estonia, Latvia, and Lithuania – SIA Scanmed

Moldova – Smart Medical Solutions

Montenegro and Serbia – Mar Medica, d.o.o.

The Company also announced the change of the company's distributor in the United Kingdom to Chalice Medical Ltd., with a focus on England and Ireland.

Dr. Christian Steiner, Senior Vice President of Sales and Marketing of CytoSorbents Corporation stated, "There is continued strong interest among clinicians and researchers from many countries around the world who have heard or learned about our CytoSorb therapy from international congresses and colleagues.  They are hearing the positive experiences and are seeing the clinical data on how CytoSorb is helping to control deadly inflammation in critically-ill and cardiac surgery patients. We are pleased to expand the global footprint of CytoSorb and to partner with these exceptional medical distributors to make CytoSorb available to all patients in need, wherever and whenever possible."

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 53 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist.  CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents is conducting its pivotal REFRESH 2-AKI trial – a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury.  CytoSorb® has been used in more than 40,000 human treatments to date.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly $22 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique patented blood purification technology including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company's websites at and or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 8, 2018, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. 

CytoSorbents Contact:

Amy Vogel

Investor Relations


Investor Relations Contact:

Jeremy Feffer

LifeSci Advisors 


Public Relations Contact:

Joshua Berkman

Rubenstein Public Relations


Editor Details

Related Links

Last Updated: 31-Jul-2018